A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer.
Li Y, Chu Y, Shi G, Wang X, Ye W, Shan C, Wang D, Zhang D, He W, Jiang J, Ma S, Han Y, Zhao Z, Du S, Chen Z, Li Z, Yang Y, Wang C, Xu X, Wu H.
Li Y, et al. Among authors: du s.
Acta Pharm Sin B. 2022 Nov;12(11):4165-4179. doi: 10.1016/j.apsb.2022.05.003. Epub 2022 May 10.
Acta Pharm Sin B. 2022.
PMID: 36386477
Free PMC article.